Fragment książki Jeffrey’a P. Okesona Leczenie dysfunkcji skroniowo‑żuchwowej i zaburzeń zwarcia, pod redakcją naukową wydania polskiego Katarzyny Grocholewicz

PIŚMIENNICTWO

1. Wu YL, Chang LY, Lee HC i wsp. Sleep distrurbances in fibromyal­gia: a meta-analysis of case-conrol studies. J Psychosom Res. 2017; 96: 89-97.
2. Alves B, Zakka TM, Teixeira MJ i wsp. Depression, sexuality and fibro­myalgia syndrome: clinical fi ndings and correlation to hematological parameters. Arq Neuropsiquiatr. 2016; 74(11): 863-868.
3. Bennett RM, Friend R, Marcus D i wsp. Criteria for the diagnosis of fi­bromyalgia: validation of the modified 2010 preliminary american col­lege of rheumatology criteria and the development of alternative crite­ria. Arthritis Care Res (Hoboken). 2014; 66(9): 1364-1373.
4. Bennett RB, Campbell S, Burckhardt C i wsp. A multidisciplinary ap­proach to fibromyalgia management. J Musculoskel Med. 1991; 8: 21.
5. Affaitati G, Costantini R, Fabrizio A i wsp. Effects of treatment of peri­pheral pain generators in fibromyalgia patients. Eur J Pain. 2011; 11(6): 516-527.
6. Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha­2-delta) ligand for the management of fibromyalgia. Am J Managed Care. 2010; 16(Suppl 5): S138-S143.
7. Emir B, Murphy TK, Petersel DL i wsp. Treatment response to pregaba­lin in fibromyalgia pain: effect of patient baseline characteristics. Exp Opin Pharmacother. 2010; 11(14): 2275-2280.
8. Roskell NS, Beard SM, Zhao Y i wsp. A meta-analysis of pain respon­se in the treatment of fi bromyalgia. Pain Pract. 2011; 15(1): 61-69.
9. Tzellos TG, Toulis KA, Goulis DG i wsp. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analy­sis. J Clin Pharm Ther. 2010; 35(6): 639-656.
10. Silverman SL, Backonja M, Pauer L i wsp. Effect of baseline characte­ristics on the response to pregabalin in fibromyalgia patients with co­morbid depression. Pain Med. 2018; 19(3): 419-428.
11. Kim SC, Landon JE, Solomon DH. Clinical characteristics and medi­cation uses among fibromyalgia patients newly prescribed amitripty­line, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (Hobo­ken). 2013; 65(11): 1813-1819.
12. Ang DC, Kaleth AS, Bigatti S i wsp. Research to Encourage Exercise for Fibromyalgia (REEF): use of motivational interviewing design and me­thod. Contemp Clin Trials. 2011; 32(1): 59-68.
13. Pierce CJ, Gale EN. A comparison of diff erent treatments for noctur­nal Bruxism. J Dent Res. 1988; 67(3): 597-601.
14. Solberg WK, Clark GT, Rugh JD. Nocturnal electromyographic evalu¬ation of bruxism patients undergoing short term splint therapy. J Oral Rehabil.1975; 2(3): 215-223.
15. Gowans SE. Fibromyalgia: increased regular physical activity as “exer¬cise” in fibromyalgia. Nat Rev Rheumatol. 2010; 6(9): 499-500.
16. Hauser W, Klose P, Langhorst J i wsp. Efficacy of different types of ae¬robic exercise in fibromyalgia syndrome: a systematic review and me¬ta-analysis of randomised controlled trials. Arthritis Res Ther. 2010; 12(3): R79.
17. Mannerkorpi K, Nordeman L, Cider A i wsp. Does moderate- to-high intensity Nordic walking improve functional capacity and pain in fi¬bromyalgia? A prospective randomized controlled trial. Arthritis Res Ther. 2010; 12(5): R189.
18. Sanudo B, Galiano D, Carrasco L i wsp. Aerobic exercise versus com¬bined exercise therapy in women with fibromyalgia syndrome: a ran¬domized controlled trial. Arch Phys Med Rehabil. 2010; 91(12): 1838- 1843.
19. Bidonde J, Bush AJ, Schachter CL i wsp. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017; 6: CD012700.
20. Del Pozo-Cruz J, Alfonso-Rosa RM, Castillo-Cuerva A i wsp. Depres¬sion symptoms are associated with key health outcomes in women with fibromyalgia: a cross-sectional study. Int J Rheum Dis. 2017; 20(7): 798-808.
21. Granges G, Littlejohn GO. A comparative study of clinical signs in fibro¬myalgia/fibrositis syndrome, healthy and exercising subjects. J Rheu¬matol. 1993; 20: 344-351.
22. Ramfjord SP. Dysfunctional temporomandibular joint and musclem¬pain. J Prosthet Dent. 1961; 11: 353-362.
23. Turk DC, Zaki HS, Rudy TE: Eff ects of intraoral appliance and bio¬feedback/ stress management alone and in combination in treating pain and depression in patients with temporomandibular disorders. J Prosthet Dent. 1993; 70(2): 158-164.
24. Ramfjord S. Bruxism: a clinical and electromyographic study. J Am Dent Assoc. 1961; 62: 21-28.
25. Arnold M. Bruxism and the occlusion. Dent Clin North Am. 1981; 25(3): 395-407.
26. Ramfjord SP, Ash MM. Occlusion. Philadelphia; 1983.
27. Graf H. Bruxism. Dent Clin North Am. 1969; 13(3): 659-665.
28. Shore NA. Occlusal Equilibration and Temporomandibular Joint Dys¬function. Philadelphia; 1959: 352-359.
29. Posselt U. The temporomandibular joint syndrome and occlusion. J Prosthet Dent. 1971; 25(4): 432-438.
30. Rugh JD, Barghi N, Drago CJ. Experimental occlusal discrepancies and nocturnal bruxism. J Prosthet Dentist. 1984; 51(4): 548-553.
31. Bailey JO, Rugh JD. Effects of occlusal adjustment on bruxism as mo¬nitored by nocturnal EMG recordings. J Dent Res. 1980; 59: 317. (spe¬cial issue).
32. Rugh JD, Solberg WK. Electromyographic studies of bruxist behavior before and during treatment. J Calif Dent Assoc. 1975; 3(9): 56-59.
33. Solberg WK, Flint RT, Brantner JP. Temporomandibular joint pain and dysfunction: a clinical study of emotional and occlusal components. J Prosthet Dentist. 1972; 28(4): 412-422.
34. Bertazzo-Silveira E, Kruger CM, Porto De Toledo I i wsp. Association between sleep bruxism and alcohol, caffeine, tobacco, and drug abuse: a systematic review. J Am Dent Assoc. 2016; 147(11): 859-866.
35. Franks AST. Conservative treatment of temporomandibular joint dys¬function: a comparative study. Dent Pract Dent Rec. 1965; 15: 205-210.
36. Okeson JP, Moody PM, Kemper JT i wsp. Evaluation of occlusal splint therapy and relaxation procedures in patients with temporomandibu¬lar disorders. J Am Dent Assoc. 1983; 107(3): 420-424.
37. Okeson JP, Kemper JT, Moody PM. A study of the use of occlusion splints in the treatment of acute and chronic patients with cranioman¬dibular disorders. J Prosthet Dent. 1982; 48(6): 708-712.
38. Okeson JP. Th e eff ects of hard and soft occlusal splints on nocturnal bruxism. J Am Dent Assoc. 1987; 114(6): 788-791.
39. Fuchs P. Th e muscular activity of the chewing apparatus during night sleep. An examination of healthy subjects and patients with functio¬nal disturbances. J Oral Rehabil. 1975; 2(1): 35-48.
40. Sheikholeslam A, Holmgren K, Riise C. A clinical and electromy¬ographic study of the long-term effects of an occlusal splint on the temporal and masseter muscles in patients with functional disorders and nocturnal bruxism. J Oral Rehabil. 1986; 13(2): 137-145.
41. Raphael KG, Janal MN, Sirois DA i wsp. Validity of self-reported sleep bruxism among myofascial temporomandibular disorder patients and controls. J Oral Rehabil. 2015; 42(10): 751-758.
42. Raphael KG, Sirois DA, Janal MN i wsp. Sleep bruxism and myofascial temporomandibular disorders: a laboratory-based polysommographic investigation. J Am Dent Assoc. 2012; 143(11): 1223-1231.
43. Lavigne GJ, Khoury S, Abe S, i wsp. Bruxism physiology and patho¬logy: an overview for clinicians. J Oral Rehabil. 2008; 35(7): 476-494.
44. Brandner CR, Warmington SA. Delayed onset muscle soreness and per¬ceived exertion following blood flow restriction exercise. J Strength Cond Res. 2017.
45. Delcour L, Dallaudiere B, Omoumi P i wsp. Delayed onset muscleso¬reness. JBR-BTR. 2014; 97(5): 313.
46. Tsukiyama Y, Baba K, Clark GT. An evidence-based assessment of occ¬lusal adjustment as a treatment for temporomandibular disorders. J Prosthet Dent. 2001; 86(1): 57-66.
47. Hiyama S, Ono T, Ishiwata Y i wsp. First night effect of an interocclu¬sal appliance on nocturnal masticatory muscle activity. J Oral Reha¬bil. 2003; 30(2): 139-145.
48. Matsumoto H, Tsukiyama Y, Kuwatsuru R i wsp. The effect of intermit¬tent use of occlusal splint devices on sleep bruxism: a 4-week observa¬tion with a portable electromyographic recordingdevice. J Oral Reha¬bil. 2015; 42(4): 251-258.
49. Saletu A, Parapatics S, Saletu B i wsp. On the pharmacotherapy of sle¬ep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam. Neuropsychobiology. 2005; 51(4): 214-225.
50. Clarke NG, Townsend GC, Carey SE. Bruxing patterns in man during sleep. J Oral Rehabil. 1983; 11(2): 123-127.
51. Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED i wsp. Clinical eva¬luation of amitriptyline for the control of chronic pain caused by tem¬poromandibular joint disorders. Cranio. 2003; 21(3): 221-225.
52. Plesh O, Curtis D, Levine J i wsp. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil. 2000; 27(10): 834-841.
53. Herman CR, Schiffman EL, Look JO i wsp. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to pa¬tient education and self-care for the treatment of jaw pain upon awa¬kening: a randomized clinical trial. J Orofac Pain. 2002; 16(1): 64-70.
54. 54 Glaros AG, Williams K, Lausten L. The role of parafunctions, emotions and stress in predicting facial pain. J Am Dent Assoc. 2005; 136(4): 451-458.
55. Schmitter M, Kares-Vrincianu A, Kares H i wsp. Sleep-associated aspects of myofascial pain in the orofacial area among temporoman¬dibular disorder patients and controls. Sleep Med. 2015; 16(9): 1056- 1061.
56. Lavigne GJ, Sassle BJ. Th e neurobiology of orofacial pain and sleep and their interactions. J Dent Res. 2016; 95(10): 1109-1116.
57. Glaros AG, Forbes M, Shanker J i wsp. Effect of parafunctional clen¬ching on temporomandibular disorder pain and proprioceptive awa¬reness. Cranio. 2000; 18(3): 198-204.
58. Holmgren K, Sheikholeslam A, Riise C. Effect of a full-arch maxilla¬ry occlusal splint on parafunctional activity during sleep in patients with nocturnal bruxisn and signs and symptoms of craniomandibular disorders. J Prosthet Dent. 1993; 69: 293-297.
59. Carlson CR, Sherman JJ, Studts JL i wsp. The effects of tongue position on mandibular muscle activity. J Orofac Pain. 1997; 11(4):291-297.
60. Glaros AG, Kim-Weroha N, Lausten L i wsp. Comparison of habit rever¬sal and a behaviorally-modifi ed dental treatment for temporomandi¬bular disorders: a pilot investigation. Appl Psychophysiol Biofeedback. 2007; 32(3-4): 149-154.
61. Carlson C, Bertrand P, Ehrlich A i wsp. Physical self-regulation tra¬ining for the management of temporomandibular disorders. J Orofac Pain. 2001; 15: 47-55.
62. Anderson DM. Dorland’s Illustrated Medical Dictionary. Philadelphia; 1994.
63. Tolosa E, Marti MJ. Blepharospasm-oromandibular dystonia syndro¬me (Meige’s syndrome): clinical aspects. Adv Neurol. 1988; 49: 73-84.
64. Jankovic J. Etiology and diff erential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49: 103-116.
65. Cardoso F, Jankovic J. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995; 52(3): 263-270.
66. Miyaoka T, Miura S, Seno H i wsp. Jaw-opening dystonia (Brueghel’s syndrome) associated with cavum septi pellucidi and Verga’s ventric¬le: a case report. Eur J Neurol. 2003; 10(6): 727-729.
67. Nutt JG, Muenter MD, Aronson A i wsp. Epidemiology of focal and ge¬neralized dystonia in Rochester, Minnesota. Mov Disord. 1988; 3(3): 188-194.
68. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibu¬lar dystonia: long-term follow-up. Neurology. 1999; 53(9): 2102-2107.